BioWorld Asia

March 28, 2007

Algeta Grosses $41M In IPO To Advance Alpharadin Trials

Algeta ASA's IPO on the Oslo Stock Exchange hit the upper end of its target, raising gross proceeds of slightly less than NOK250 million (US$41.1 million). (BioWorld International) Read More

VASTox On Buying Spree; Next Item: A New Identity

Gene Related to Biological Clock Also Has Role in DNA Repair

TiGenix Stocks Gobbled Up As Belgian Biotechs Soar

Clinuvel Adds New Indication For Tanner Turned Compound

EU OKs Three GM Products But Withdraws Five Others

Other News To Note

ProFibrix Raises $11M For User-Friendly Fibrinogen

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...